A phase II randomized trial of gefitinib alone or with Tegafur/uracil treatment in patients with pulmonary adenocarcinoma who had failed previous chemotherapy

Journal of Thoracic Oncology

Volumn 6, Issue 6, 2011, Pages 1110-1116

  Chen, Yuh Min ^a,b,c   Fan, Wen Chien ^d   Tsai, Chun Ming ^a,b   Liu, Shih Hao ^e   Shih, Jen Fu ^a   Chou, Teh Ying ^a   Wu, Chieh Hung ^a   Chou, Kun Ta ^a   Lee, Yu Chin ^a   Perng, Reury Perng ^a   Whang Peng, Jacqueline ^c  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d Chutung Veterans General Hospital   (Taiwan)

^e Koo Foundation Sun Yat Sen Cancer Centre   (Taiwan)

Author keywords

Epidermal growth factor receptor (EGFR); Gefitinib; Non small cell lung cancer; Salvage therapy; UFT (tegafur uracil)

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; ORZEL;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; DRUG EFFICACY; FEMALE; GENE MUTATION; HUMAN; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MICROVASCULATURE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SEQUENCE ANALYSIS; TREATMENT FAILURE;

EID: 79958120436     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3182121c09     Document Type: Article

References (32)

1. Azzoli CG, Giaccone G, Temin S. American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Oncol Practice 2010;6:39-43.
2. Shepherd FA, Pereira JR, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-132. (Pubitemid 41058344)
3. Kim ES, Hirsch V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008;372:1809-1818.
4. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366: 1527-1537. (Pubitemid 41540110)
5. Perng RP, Yang CH, Chen YM, et al. High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy. Lung Cancer 2008;62:78-84.
6. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1. J Clin Oncol 2004;22:777-784. (Pubitemid 41103588)
7. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2. J Clin Oncol 2004;22:785-794. (Pubitemid 41103589)
8. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005;23:5892-5899.
9. Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007;25:1545-1552. (Pubitemid 46733081)
10. Davies AM, Ho C, Lara PN Jr, et al. Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer. Clin Lung Cancer 2006;7:385-388. (Pubitemid 44043547)
11. Hotta K, Matsuo K, Ueoka H, et al. Role of adjuvant chemotherapy in patients with resected non-small-cell lung cancer: reappraisal with a meta-analysis of randomized controlled trials. J Clin Oncol 2004;22: 3860-3867. (Pubitemid 41079866)
12. Langer CJ. The role of tegafur/uracil in pulmonary malignancy. Drugs 1999;58(Suppl 3):71-75. (Pubitemid 30192617)
13. Ichinose Y, Yosimori K, Yoneda S, et al. UFT plus cisplatin combination chemotherapy in the treatment of patients with advanced non-small cell lung carcinoma: a multi-institutional phase II trial. For the Japan UFT Lung Cancer Study Group. Cancer 2000;88:318-323. (Pubitemid 30051815)
14. Saito J, Nakai Y, Saijo Y, et al. A phase II trial of oral UFT plus cisplatin (CDDP) in patients with non-small cell lung cancer (NSCLC). Lung Cancer 2001;31:285-293. (Pubitemid 32109240)
15. Yonekura K, Basaki Y, Chikahisa L, et al. UFT and its metabolites inhibit the angiogenesis induced by murine renal cell carcinoma, as determined by a dorsal air sac assay in mice. Clin Cancer Res 1999;5: 2185-2191. (Pubitemid 29399276)
16. Basaki Y, Chikahisa L, Aoyagi K, et al. gamma-Hydroxybutyric acids and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor. Angiogenesis 2001;4:163-173. (Pubitemid 34174305)
17. Tanaka F, Yanagihara K, Otake Y, et al. Angiogenesis and the efficacy of postoperative administration of UFT in pathologic stage I non-small cell lung cancer. Cancer Sci 2004;95:371-376. (Pubitemid 38519480)
18. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004;4:423-436. (Pubitemid 38745528)
19. Herbst RS, Onn A, Sandler A. Angiogenesis and lung cancer: prognostic and therapeutic implications. J Clin Oncol 2005;23:3243-3256. (Pubitemid 46211349)
20. Chen YM, Perng RP, Tsai CM. Gefitinib treatment is highly effective in non-small-cell lung cancer patients failing previous chemotherapy in Taiwan: a prospective phase II study. J Chemother 2005;17:679-684.
21. Chen YM, Liu JM, Chou TY, et al. Phase II randomized study of gefitinib daily treatment alone or plus vinorelbine every 2 weeks treatment in patients with adenocarcinoma of the lung who failed at least two regimens of chemotherapy. Cancer 2007;109:1821-1828. (Pubitemid 46668546)
22. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216. (Pubitemid 30099779)
23. Simon R, Wittes RE, Ellenberg SS. Randomized phase II clinical trials. Cancer Treat Rep 1985;69:1375-1381. (Pubitemid 16163075)
24. Weidner N. Tumor vascularity and proliferation: clear evidence of a close relationship. J Pathol 1999;189:297-299. (Pubitemid 29489212)
25. Kosaka T, Yatabe Y, Endoh H, et al. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004;64:8919-8923. (Pubitemid 39665498)
26. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97:339-346. (Pubitemid 40425952)
27. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139. (Pubitemid 38637993)
28. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304: 1497-1500. (Pubitemid 38720929)
29. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. New Engl J Med 2009;361: 947-957.
30. Huang C, Liu D, Masuya D, et al. Clinical application of biological markers for treatments of resectable non-small-cell lung cancers. Br J Cancer 2005;92:1231-1239. (Pubitemid 40604397)
31. Suehisa H, Toyooka S, Hotta K, et al. Epidermal growth factor receptor mutation status and adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. J Clin Oncol 2007;25:3952-3957. (Pubitemid 47477273)
32. Uzzan B, Nicolas P, Cucherat M, et al. Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis. Cancer Res 2004;64:2941-2955. (Pubitemid 38581387)